Sign in
Taking people in United KingdomNo phase

Safety of an Experimental Tuberculosis Vaccine in Healthy Adult Volunteers

Tests a new tuberculosis vaccine, ID93/GLA-SE, in healthy adults, with and without prior BCG.

Key facts

Who runs it
University of Oxford
Where
Oxford, United KingdomSee the site
Trial code
Registry title
ID93/GLA-SE Vaccination + BCG Challenge
Status
Recruiting
People taking part
48 people, planned
Started
18 Dec 2024
Expected to end
31 Jul 2027
Type of study
Interventional, 4 groups
Treatments tested
  • ID93/GLA-SE
  • BCG Danish
Record updated
22 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults aged 18-55 who live in or near Oxford. Some have had the BCG vaccine in the past and some have not.

Age
18 to 55 years
Sex
All sexes can join.
Earlier treatment
People must either have had the BCG vaccine at least 12 months before enrolment (scar or records) or never have had it. People who had treatment for TB, an investigational TB vaccine or aerosolised BCG cannot join.
Biomarker or test result
The screening IGRA (interferon gamma release assay) blood test must be negative.

Main reasons for not taking part

  • Current smoker, including e-cigarettes, in the last 3 months
  • Clinically significant respiratory disease, including asthma
  • Past or current TB disease or latent TB infection
  • HIV, Hepatitis B or Hepatitis C infection
  • Pregnancy, breastfeeding or plans to become pregnant during the study

This trial only enrols healthy participants. The registry sentence this rests on: Healthy adults aged 18-55 years

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • The participant must satisfy all the following criteria to be eligible for the study:
  • Healthy adults aged 18-55 years
  • Resident in or near Oxford for the duration of the study period
  • Provide written informed consent
  • Willing to allow the investigators to discuss the participant's medical history with their General Practitioner (or review summary care record, if available)
  • Allow the investigator to register volunteer details with a confidential database (The Over-volunteering Protection Service) to prevent concurrent entry into clinical studies/trials
  • Agreement to refrain from blood donation during the course of the study
  • For persons of child-bearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening, vaccination, challenge and bronchoscopy
  • Able and willing (in the investigator's opinion) to comply with all study requirements
  • No clinically relevant findings in medical history or on physical examination
  • Screening IGRA (interferon gamma release assay) negative
  • Willing to be tested for evidence of COVID-19 infection and to allow public health notification of the results if required
  • EITHER Previously vaccinated with the BCG (at least 12 months prior to enrolment, as evidenced by a visible scar or documentation in medical or occupational health records) OR Never previously vaccinated with BCG and no evidence of BCG scar at physical examination

Who cannot take part

  • Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment or during the trial follow up period
  • Previous diagnosis or treatment for TB disease or latent TB infections
  • Previous receipt of any investigational TB vaccine or aerosolised BCG
  • Concurrent use of oral, inhaled or systemic steroid medication or use for more than 14 days within the last 6 months (steroids used as a cream or ointment are permissible), or the use of other immunosuppressive agents concurrently or for more than 14 days within the last 6 months
  • Administration of a live vaccine within the preceding 28 days prior to enrolment, or plan for such prior to aerosol challenge
  • Administration of any other non-live vaccine within the preceding 14 days prior to enrolment
  • Current use of any medication or other drug taken through the nasal or inhaled route including cocaine or other recreational drugs
  • Previously resident for more than 12 months concurrently in the rural areas of a tropical climate where significant non-tuberculous mycobacterial exposure is likely
  • Any clinically significant respiratory disease, including asthma
  • History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study agent, any essential study procedure, sedative drugs, or any local or general anaesthetic agents
  • History of allergic reaction to Kanamycin or kanamycin-related antibiotics
  • Clinically significant history of skin disorder, allergy, atopy, cancer (except basal cell carcinoma of the skin or carcinoma in situ of the cervix), bleeding disorder, cardiovascular disease (including uncontrolled hypertension), gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse
  • Any significant autoimmune conditions or immunodeficiency (including current HIV)
  • Currently infected with HIV, Hepatitis B or Hepatitis C based on positive serological testing (Hepatitis B surface antigen, Hepatitis C virus or HIV antibodies) and confirmatory molecular testing if indicated
  • Shares a household with someone with clinically significant immunodeficiency (either from infection or medication) who is deemed to be at risk of developing disseminated BCG infection if exposed to BCG
  • Any other significant disease, disorder, or finding, which, in the opinion of the investigator, may either put the volunteer at risk, affect the participant's ability to participate in the study or impair interpretation of the study data
  • Clinical, radiological, or laboratory evidence of current active TB disease or latent TB infection
  • The participant may not enter the study if any of the following apply:
  • Current smoker (defined as any smoking including e-cigarettes in the last 3 months)
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned enrolment date
  • Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy
  • Pregnancy, lactation or intention to become pregnant during study period
  • Clinically significant abnormality on screening chest radiograph
  • Clinically significant abnormality of lung function testing
  • Any clinically significant abnormality of screening blood or urine tests
  • A body mass index (BMI) of <18.5 or >45

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United Kingdom

  • Centre for Clinical Vaccinology and Tropical MedicineOxford, United KingdomContact: Lisa Deakin, BScTaking people

About the trial

What the trial wants to find out

The purpose of this study is to:

Read full original descriptionShow less

1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2. Provide preliminary immunogenicity data of this novel TB vaccine (ID93/GLA-SE).

This clinical trial will apply an aerosol BCG challenge model involving 48 participants - 24 historically BCG-vaccinated volunteers and 24 BCG-naïve volunteers. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity.

The 4 groups in the trial

  • Group A: 2 doses of ID93/GLA-SE with 1 x 10^6 cfu BCG (historically BCG-vaccinated group)Treatment being tested

    12 historically BCG-vaccinated participants will be vaccinated with 2 doses of ID93/GLA-SE and after 112 days receive 1 x 10\^6 cfu aerosol inhaled BCG as a challenge. All Group A participants will have a bronchoscopy 14 days post challenge.

    Treatment: ID93/GLA-SE and BCG Danish

  • Group B: 1 x 10^6 cfu BCG (historically BCG-vaccinated group)Treatment being tested

    12-16 historically BCG-vaccinated participants will receive 1 x 10\^6 cfu aerosol inhaled BCG. All Group B participants will have a bronchoscopy 14 days post challenge.

    Treatment: BCG Danish

  • Group C: 2 doses of ID93/GLA-SE with 1 x 10^6 cfu BCG (BCG-naïve group)Treatment being tested

    12 BCG-naïve participants will be vaccinated with 2 doses of ID93/GLA-SE and after 112 days receive 1 x 10\^6 cfu aerosol inhaled BCG as a challenge. All Group C participants will have a bronchoscopy 14 days post challenge.

    Treatment: ID93/GLA-SE and BCG Danish

  • Group D: 1 x 10^6 cfu BCG (BCG-naïve group)Treatment being tested

    12-16 BCG-naïve participants will receive 1 x 10\^6 cfu aerosol inhaled BCG. All Group D participants will have a bronchoscopy 14 days post challenge.

    Treatment: BCG Danish

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Trial Evaluating the Safety of an Aerosol BCG Controlled Human Infection Model in Assessing the Immunogenicity of Historical BCG Vaccination and Vaccination With ID93/GLA-SE in Healthy Adult Participants
Plain-language title
Safety of an Experimental Tuberculosis Vaccine in Healthy Adult VolunteersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06670755, who can take part
Record updated
22 October 2026